A detailed history of Price T Rowe Associates Inc transactions in Axogen, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 31,600 shares of AXGN stock, worth $407,640. This represents 0.0% of its overall portfolio holdings.

Number of Shares
31,600
Previous 31,173 1.37%
Holding current value
$407,640
Previous $226,000 96.46%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$7.52 - $14.69 $3,211 - $6,272
427 Added 1.37%
31,600 $444,000
Q2 2024

Aug 14, 2024

BUY
$5.67 - $8.06 $8,635 - $12,275
1,523 Added 5.14%
31,173 $226,000
Q1 2024

May 15, 2024

BUY
$6.63 - $10.69 $14,612 - $23,560
2,204 Added 8.03%
29,650 $240,000
Q4 2023

Feb 14, 2024

SELL
$3.61 - $7.76 $13,797 - $29,658
-3,822 Reduced 12.22%
27,446 $188,000
Q3 2023

Nov 14, 2023

BUY
$4.68 - $9.26 $44,478 - $88,007
9,504 Added 43.67%
31,268 $157,000
Q2 2023

Aug 14, 2023

BUY
$8.5 - $10.38 $1,530 - $1,868
180 Added 0.83%
21,764 $199,000
Q1 2023

May 15, 2023

SELL
$7.53 - $10.95 $7 - $10
-1 Reduced -0.0%
21,584 $204,000
Q4 2022

Feb 14, 2023

BUY
$9.44 - $13.09 $7,835 - $10,864
830 Added 4.0%
21,585 $215,000
Q3 2022

Nov 14, 2022

BUY
$8.14 - $12.25 $20,561 - $30,943
2,526 Added 13.86%
20,755 $248,000
Q2 2022

Aug 15, 2022

SELL
$6.99 - $10.0 $2,334 - $3,340
-334 Reduced 1.8%
18,229 $149,000
Q1 2022

May 16, 2022

BUY
$7.26 - $10.7 $55,778 - $82,208
7,683 Added 70.62%
18,563 $147,000
Q4 2021

Feb 14, 2022

SELL
$8.8 - $16.0 $3,916 - $7,120
-445 Reduced 3.93%
10,880 $102,000
Q3 2021

Nov 15, 2021

SELL
$15.23 - $21.72 $1,523 - $2,172
-100 Reduced 0.88%
11,325 $179,000
Q2 2021

Aug 16, 2021

BUY
$17.8 - $23.5 $14,685 - $19,387
825 Added 7.78%
11,425 $247,000
Q1 2021

May 17, 2021

BUY
$17.18 - $22.6 $182,108 - $239,560
10,600 New
10,600 $215,000

Others Institutions Holding AXGN

About Axogen, Inc.


  • Ticker AXGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 42,283,700
  • Market Cap $545M
  • Description
  • AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgic...
More about AXGN
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.